92 related articles for article (PubMed ID: 37289450)
1. Predictors of radioiodine (RAI)-avidity restoration for NTRK fusion-positive RAI-resistant metastatic thyroid cancers.
Syed AR; Gorana A; Nohr E; Yuan XK; Amin MASc P; Ghaznavi S; Lamb D; McIntyre J; Eszlinger M; Paschke R
Eur Thyroid J; 2024 Jun; 13(3):. PubMed ID: 38642578
[TBL] [Abstract][Full Text] [Related]
2. NTRK gene fusion testing and management in lung cancer.
Repetto M; Chiara Garassino M; Loong HH; Lopez-Rios F; Mok T; Peters S; Planchard D; Popat S; Rudzinski ER; Drilon A; Zhou C
Cancer Treat Rev; 2024 Jun; 127():102733. PubMed ID: 38733648
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and management of TRK fusion cancer.
Kummar S; Italiano A; Brose MS; Carlson JJ; Sullivan SD; Lassen U; Federman N
Am J Manag Care; 2022 Jan; 28(2 Suppl):S15-S25. PubMed ID: 35201680
[TBL] [Abstract][Full Text] [Related]
4. Phase separation underlies signaling activation of oncogenic NTRK fusions.
Zhu T; Xie J; He H; Li H; Tang X; Wang S; Li Z; Tian Y; Li L; Zhu J; Zhu G
Proc Natl Acad Sci U S A; 2023 Oct; 120(42):e2219589120. PubMed ID: 37812694
[No Abstract] [Full Text] [Related]
5. Improving outcomes in pediatric NTRK gene fusion-positive solid tumors: importance of genomic testing and targeted therapy with the TRK inhibitor larotrectinib.
Laetsch TW
Clin Adv Hematol Oncol; 2024 May; 22 Suppl 3(4):1-11. PubMed ID: 38739704
[No Abstract] [Full Text] [Related]
6. Fusion genes in pancreatic tumors.
Gkountakos A; Singhi AD; Westphalen CB; Scarpa A; Luchini C
Trends Cancer; 2024 May; 10(5):430-443. PubMed ID: 38378317
[TBL] [Abstract][Full Text] [Related]
7. ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature.
Zhang W; Tian S; Li X; Chen Y; Wang X; Zhang Y; Lv L; Li Y; Shi H; Bai C
Clin Lung Cancer; 2024 May; 25(3):215-224.e3. PubMed ID: 38584068
[TBL] [Abstract][Full Text] [Related]
8. Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature.
Gupta M; Sherrow C; Krone ME; Blais EM; Pishvaian MJ; Petricoin EF; Matrisian LM; DeArbeloa P; Gregory G; Brown A; Zalewski O; Prinzing G; Roche C; Kanehira K; Mukherjee S; Iyer R; Fountzilas C
J Natl Compr Canc Netw; 2021 Jan; 19(1):10-15. PubMed ID: 33406492
[TBL] [Abstract][Full Text] [Related]
9. Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report.
Percy C; Schubert T; Galant C; Kirchgesner T; Mazzeo F
Clin Case Rep; 2021 Mar; 9(3):1694-1698. PubMed ID: 33768917
[TBL] [Abstract][Full Text] [Related]
10. Precision Oncology Comes of Age: Tumor-Agnostic Approaches.
Lewis C; Harvey RD
J Adv Pract Oncol; 2020 Apr; 11(3):221-225. PubMed ID: 33598315
[TBL] [Abstract][Full Text] [Related]
11. Erratum: Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis.
JCO Precis Oncol; 2023 Sep; 7():e2300383. PubMed ID: 37656953
[No Abstract] [Full Text] [Related]
12. Pathogenesis of cancers derived from thyroid follicular cells.
Fagin JA; Krishnamoorthy GP; Landa I
Nat Rev Cancer; 2023 Sep; 23(9):631-650. PubMed ID: 37438605
[TBL] [Abstract][Full Text] [Related]
13. Update on current diagnosis and management of anaplastic thyroid carcinoma.
Pavlidis ET; Galanis IN; Pavlidis TE
World J Clin Oncol; 2023 Dec; 14(12):570-583. PubMed ID: 38179406
[TBL] [Abstract][Full Text] [Related]
14. Improved guidance is needed to optimise diagnostics and treatment of patients with thyroid cancer in Europe.
de la Fouchardière C; Fugazzola L; Locati LD; Alvarez CV; Peeters RP; Camacho P; Simon IM; Jarząb B; Netea-Maier R
Endocrine; 2024 Mar; 83(3):585-593. PubMed ID: 38001324
[TBL] [Abstract][Full Text] [Related]
15. Errors in Affiliations and Fourth Section of Review.
JAMA Oncol; 2023 Aug; 9(8):1155. PubMed ID: 37589997
[No Abstract] [Full Text] [Related]
16. Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas: A Review.
Haddad R; Elisei R; Hoff AO; Liu Z; Pitoia F; Pruneri G; Sadow PM; Soares F; Turk A; Williams MD; Wirth LJ; Cabanillas ME
JAMA Oncol; 2023 Aug; 9(8):1132-1141. PubMed ID: 37289450
[TBL] [Abstract][Full Text] [Related]
17. Timing of NTRK Gene Fusion Testing and Treatment Modifications Following TRK Fusion Status Among US Oncologists Treating TRK Fusion Cancer.
Klink AJ; Kavati A; Gassama AT; Kozlek T; Gajra A; Antoine R
Target Oncol; 2022 May; 17(3):321-328. PubMed ID: 35716252
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
Demetri GD; Antonescu CR; Bjerkehagen B; Bovée JVMG; Boye K; Chacón M; Dei Tos AP; Desai J; Fletcher JA; Gelderblom H; George S; Gronchi A; Haas RL; Hindi N; Hohenberger P; Joensuu H; Jones RL; Judson I; Kang YK; Kawai A; Lazar AJ; Le Cesne A; Maestro R; Maki RG; Martín J; Patel S; Penault-Llorca F; Premanand Raut C; Rutkowski P; Safwat A; Sbaraglia M; Schaefer IM; Shen L; Serrano C; Schöffski P; Stacchiotti S; Sundby Hall K; Tap WD; Thomas DM; Trent J; Valverde C; van der Graaf WTA; von Mehren M; Wagner A; Wardelmann E; Naito Y; Zalcberg J; Blay JY
Ann Oncol; 2020 Nov; 31(11):1506-1517. PubMed ID: 32891793
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
